ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2088

Annexin A1 Receptor Agonist Suppresses Development of Inflammatory Arthritis

Yuan Hang Yang1, Yuan Jia2, Wenping Kao1, Wuqi Song3, Zhan-guo Li4 and Eric F. Morand1, 1Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 2Department of Rheumatology and Immunology,Clinical Immunology Center, Peking University People's Hospital, Beijing, China, 3Harbin Medical University, Harbin, China, 4Rheumatology, Peking University People's Hospital, Beijing, China

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Animal models, inflammatory arthritis and synovial cells, synovial fluid

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Annexin A1 (AnxA1) is recognized as an endogenous anti-inflammatory molecule. An AnxA1 receptor, formyl-peptide receptor 2 (FPR2), has been identified in human and mice. The contribution of FPR2 to rheumatoid arthritis (RA) is not well understood. We investigated the contribution of AnxA1 and FPR2 to the regulation of inflammatory arthritis.

Methods: Arthritis was induced by injection of K/B×N serum (38μl/mouse, ip) in wild-type or AnxA1-/- mice at day 0 and 2. Wild-type mice were treated with Compound 43, an agonist of FPR1/2, at 6-30μg/g on days 0 – 4. RA synovial like fibroblasts (FLS) were treated with FPR2 ligand or antagonist compounds, and AnxA1 was silenced using siRNA.

Results: Deficiency of AnxA1 significantly increased arthritis clinical and histopathological severity. Treatment of wild-type mice with Compound 43 dose-dependently and significantly suppressed clinical scores (Fig 1A), paw thickness (Fig 1B) and histopathologic severity. AnxA1 silencing increased RAFLS proliferation, ERK and NFKB activation. RAFLS expressed FPR2, and an FPR ligand inhibited proliferation while, blocking FPR2 significantly increased proliferation, ERK and NF-κB activation, and IL-6 release.

Conclusion: Compound 43 was potently therapeutic in K/BxN arthritis and FPR2 regulates RAFLS activation. These data suggest that FPR2 ligands may have important beneficial actions on RA.

Figure 1. Mice were injected with KB×N serum on day 0 and 2 and Compound 43 from day 0 to 4. *P<0.05

A. Clinical scores B. Paw thickness.

Text Box: Figure 1. Mice were injected with KB×N serum on day 0 and 2 and Compound 43 from day 0 to 4. *P<0.05 A. Clinical scores B. Paw thickness.


Disclosure:

Y. H. Yang,
None;

Y. Jia,
None;

W. Kao,
None;

W. Song,
None;

Z. G. Li,
None;

E. F. Morand,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/annexin-a1-receptor-agonist-suppresses-development-of-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology